Health Data Analytics Institute (HDAI)— an AI company focused on empowering clinicians, optimizing care pathways, and improving patient outcomes — recently announced an oversubscribed $31 million Series C funding round to scale its predictive risk platform.
Several preeminent health systems, including Houston Methodist, Cleveland Clinic, and Dana-Farber Cancer Institute, collaborate with HDAI on various initiatives. HDAI’s implementation at Houston Methodist is one of the most system-wide AI/machine learning (ML) care optimization solutions in production, enabling data-informed actions by clinicians at the point of care and by population health managers at the system level. It also represents one of the largest deployments of Generative AI within healthcare. HDAI has additional collaborations with over 40 Medicare Accountable Care Organizations (ACOs), collectively generating 50 million weekly predictions for one million patients.
At the core of HDAI’s technology platform is an AI-optimized engine that incorporates explainable machine learning (ML) and Generative AI to quantify patient and population risks and pinpoint actionable clinical improvement opportunities. This platform forecasts health risks at patient, practice, institution, and/or regional levels and supports clinicians and institutions in driving performance improvements.
For example, HealthVision generates customizable lists of patients who would benefit from general case management or specific interventions. It offers a granular analysis of healthcare outcomes and costs as compared to peer practices and institutions.
It also gives physicians a highly synthesized view of individual patient’s medical histories, including detailed risk profiles, allowing them to spend more time developing individualized treatment plans and less time searching for information. HDAI augments the direct capabilities of HealthVision with experienced clinical teams who provide guidance and support to clinicians and case managers in developing AI-guided workflows.
Health Data Analytics Institute (HDAI) is a care optimization, decision support, and provider enablement company powered by big data, AI-powered analytics, expert insights, and point-of-care technology solutions. The company’s HealthVision platform uses predictive analytics and generative AI to analyze a patient’s medical history, including unstructured clinical notes and administrative data, to create a concise summary of the patient’s clinical chart, state of health, and to quantify and prioritize specific clinical risks. HDAI collaborates with leading health systems, value-based care Organizations, physician groups, and payers to improve care delivery, population health, reduce cost, and efficiently use scarce clinical resources.
KEY QUOTES:
“We are grateful for the continued support of our investors, who recognize the value to be unlocked by transforming huge volumes of health data into actionable insights. HDAI is committed to improving patient outcomes and clinician experiences through its broad platform of predictive analytics and AI technologies, and we are thrilled to have secured this additional funding which will allow us to drive continued implementation of our unique HealthVision product within top health systems nationwide.”
- Nassib Chamoun, Founder and CEO of HDAI
“While the swirling hype about AI in healthcare continues to generate exciting claims but little of genuine impact, the HDAI team is actively working with leading healthcare organizations and clinicians to improve care in ways that deliver better outcomes. I am increasingly convinced that the Company’s broad-based enterprise platform and remarkably cost-efficient business model can transform healthcare in the US.”
- Ed Kania, HDAI board member and longtime healthcare investor
”HDAI has firmly established itself through key partnerships with some of the top health systems in the country. We are confident that the company has the technology, resources, and team to deliver on the promise of AI in healthcare. We look forward to HDAI advancing its mission to enable system-wide efficiencies and improved patient care.”
- Philippe Amouyal, managing director at Invus and a lead investor in HDAI
